COPENHAGEN (Reuters) – Drug developer Novo Nordisk on Wednesday reported third-quarter earnings lifted by strong demand for its new obesity drug.
Novo reported net profit of 12.1 billion Danish crowns ($1.88 billion) in the third quarter, an 18% increase compared to the same period last year.
($1 = 6.4217 Danish crowns)
(Reporting by Nikolaj Skydsgaard; Editing by Christopher Cushing)
